On the one hand, a uniform prognosis or therapy response might represent a surrogate for a biological group, and the despair prognosis of many of these cases suggests that these patients could theoretically benefit from specific drug development for TP53 dysregulated AML in the future. This evidence concerns the gene TP53 and acute myeloid leukemia.